key: cord-0755274-sbkt6m82 authors: Marcolino, M. S.; Pires, M. C.; Ramos, L. E. F.; Silva, R. T.; Oliveira, L. M.; Carvalho, R. L. R. d.; Mourato, R. L. S.; Montalva, A. S.; Raventos, B.; Anschau, F.; Chatkin, J. M.; Nogueira, M. C. A.; Guimaraes Junior, M. H.; Vietta, G. G.; Duani, H.; Ponce, D.; Ziegelmann, P. K.; Castro, L. C. d.; Ruschel, K. B.; Cimini, C. C. R.; Francisco, S. C.; Floriani, M. A.; Nascimento, G. F.; Farace, B. L.; Monteiro, L. d. S.; Silva, M. V. R. S. e.; Sales, T. L. S.; Martins, K. P. M. P.; Nascimento, I. J. B. d.; Fereguetti, T. O.; Ferrara, D. T. M. O.; Botoni, F. A.; Etges, A. P. B. d. S.; Boersma, E title: ABC2-SPH risk score for in-hospital mortality in COVID-19 patients: development, external validation and comparison with other available scores date: 2021-02-03 journal: nan DOI: 10.1101/2021.02.01.21250306 sha: 4290b3e5462760d0a56550e6169e28b199aec24d doc_id: 755274 cord_uid: sbkt6m82 Objective: To develop and validate a rapid scoring system at hospital admission for predicting in-hospital mortality in patients hospitalized with coronavirus disease 19 (COVID-19), and to compare this score with other existing ones. Design: Cohort study Setting: The Brazilian COVID-19 Registry has been conducted in 36 Brazilian hospitals in 17 cities. Logistic regression analysis was performed to develop a prediction model for in-hospital mortality, based on the 3978 patients that were admitted between March-July, 2020. The model was then validated in the 1054 patients admitted during August-September, as well as in an external cohort of 474 Spanish patients. Participants: Consecutive symptomatic patients ([≥]18 years old) with laboratory confirmed COVID-19 admitted to participating hospitals. Patients who were transferred between hospitals and in whom admission data from the first hospital or the last hospital were not available were excluded, as well those who were admitted for other reasons and developed COVID-19 symptoms during their stay. Main outcome measures: In-hospital mortality Results: Median (25th-75th percentile) age of the model-derivation cohort was 60 (48-72) years, 53.8% were men, in-hospital mortality was 20.3%. The validation cohorts had similar age distribution and in-hospital mortality. From 20 potential predictors, seven significant variables were included in the in-hospital mortality risk score: age, blood urea nitrogen, number of comorbidities, C-reactive protein, SpO2/FiO2 ratio, platelet count and heart rate. The model had high discriminatory value (AUROC 0.844, 95% CI 0.829 to 0.859), which was confirmed in the Brazilian (0.859) and Spanish (0.899) validation cohorts. Our ABC2-SPH score showed good calibration in both Brazilian cohorts, but, in the Spanish cohort, mortality was somewhat underestimated in patients with very high (>25%) risk. The ABC2-SPH score is implemented in a freely available online risk calculator (https://abc2sph.com/). Conclusions: We designed and validated an easy-to-use rapid scoring system based on characteristics of COVID-19 patients commonly available at hospital presentation, for early stratification for in-hospital mortality risk of patients with COVID-19. What is already known on this topic? • Rapid scoring systems may be very useful for fast and effective assessment of COVID-19 patients in the emergency department. • The majority of available scores have high risk of bias and lack benefit to clinical decision making. • Derivation and validation studies in low-and middle-income countries, including Latin America, are scarce. • ABC 2 -SPH employs seven well defined variables, routinely assessed upon hospital presentation: age, number of comorbidities, blood urea nitrogen, C reactive protein, Spo2/FiO2 ratio, platelets and heart rate. • This easy-to-use risk score identified four categories at increasing risk of death with a high level of accuracy, and displayed better discrimination ability than other existing scores. • A free web-based calculator is available and may help healthcare practitioners to estimate the expected risk of mortality for patients at hospital presentation. Coronavirus disease 2019 , caused by the SARS-CoV-2 virus, is still the main global health, social and economic challenge, overwhelming health care systems in many countries and heavily burdening others, with over 102 million cases and 2.2 million deaths worldwide. 1,2 While some countries have been declining in new cases, many others have been experiencing a worse surge of the disease than the first wave. Latin America is currently worst-hit region of COVID-19 cases in the world, along with Asia. 3, 4 Case rates continue to rise, and some hospitals are nearly at their full capacity of intensive care unit beds. The emergence of the new variants of SARS-CoV-2 in England, South Africa and Brazil, with very high viral growth, potentially more transmissible, less detectable with the RT-PCR technique and an unknown response to the available vaccines, is currently a cause of huge concern 5-7 . Fast and efficient assessment of prognosis of the disease is needed to optimize the allocation of health care and human resources, to empower early identification and intervention of patients at higher risk of poor outcome. A proper assessment tool will guide decision making to develop an appropriate plan of care for each patient 8 . In this context, rapid scoring systems, which combine different variables to estimate the risk of a poor outcome, may be extremely helpful for quick and effective assessment of those patients in the emergency department 9 . Although different scoring systems have been proposed to assess prognosis in COVID-19 patients, the majority of them lack benefit to clinical decision making, and there is a lack of reliable prognostic prediction models 10, 11 . Most scores were developed from small cohorts, at high risk for bias, with selected study samples and relatively few outcome events, without clear details of model derivation and validation, as well as unclear reporting on intended use [12] [13] [14] [15] [16] . These issues lead to a high risk of model overfitting, thus their predictive performance when used in clinical practice may be different than that reported. 11, 12 Additionally, clinical characteristics of COVID-19 patients and disease severity vary in different studies in different countries 17 , and external validation was rarely done. Derivation and validation studies in low-and middle-income countries, including Latin America, are scarce 11 . In this context, our aim was to develop and validate an easy applicable rapid scoring system that employs routinely available clinical and laboratory data at hospital presentation, to predict in-hospital mortality in patients with COVID-19, able to discriminate high vs non-high risk patients. Additionally, we aimed to compare this score with other existing ones. This study is part of the Brazilian COVID-19 Registry, an ongoing multicenter observational study described elsewhere 18 Consecutive patients with laboratory-confirmed COVID-19 admitted to the participating hospitals from March 1 to September 30, 2020 were enrolled. COVID-19 diagnosis was confirmed according to the World Health Organization guidance 21 . For the purpose of the present study, eligible patients were ≥ 18 years-old and had completed hospitalization (i.e., discharge or death). Patients who were transferred between hospitals and admission data from the first hospital (as we aimed to develop a score to be used in the first assessment) or the last hospital was not available were excluded, as well those who were admitted for other reasons and developed COVID-19 symptoms during their stay (as their information from the first assessment would be biased, and their profile is different from the other patients ) (Figure 1 ). Those who were admitted for other reasons were excluded. Although patients who were transferred to another hospital where we could not get the final outcome were excluded, a comparison of the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250306 doi: medRxiv preprint clinical characteristics with patients who were included is provided in the Supplemental Material (Table S1) . Demographic information, clinical characteristics, laboratory and outcome data were collected from the medical records by using a prespecified case report form applying Research Electronic Data Capture (REDCap) tools 22,23 hosted at the Telehealth Center, University Hospital, Universidade Federal de Minas Gerais. Data were collected by trained hospital staff or interns. A detailed data management plan (DMP) was developed and provided to all participating centers. An online DMP training was mandatory before local research personnel were allowed to start collecting study data 24 . We undertook comprehensive data quality checks to ensure high quality. A code was developed in R software to identify values likely related to data entry errors for vital signs and laboratory variables, based on expert-guided rules. Data were sent to each center for checking and correction. Transfers from one participant hospital to another were merged and considered as a single visit. All variables used to calculate the risk score were obtained at hospital admission. A set of potential predictor variables for in-hospital mortality was selected a priori, as recommended 19 , taking into account the evidence in literature of association with worse prognosis in patients with COVID-19 or pneumonia, and availability of predictor measurement at the time the model would be used, i.e., hospital admission. We considered predictors that would be available in routine practice in most emergency departments worldwide. It included patient demographic characteristics, pre-existing comorbid medical conditions, home medications, clinical assessment at admission and laboratory data 12 . All laboratory tests were performed at the discretion of the treating physician. Imaging test results were not included, as X-ray and CT scan are not always performed at patient admission and their interpretation involve subjective judgement. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250306 doi: medRxiv preprint Candidate predictor variables which were not available for at least two thirds of patients within the derivation cohort (more than one third of missing data) were excluded. Continuous variables were summarized using medians and interquartile ranges (IQR), whereas we used counts and percentages for categorical variables. We reported 95% confidence intervals, and for all two-tailed-tests performed, a p-value less than 0.05 was considered statistically significant. Statistical analysis was performed with R software (version 4.0.2) with the mgcv, finalfit, mice, glmnet, pROC, rms, rmda, and psfmi packages. Details about how missing data were handled, as well as modelbuilding and model-validation procedures, are described below. Considering missing at random after analyzing missing data patterns, multiple imputation with chained equations (MICE) was used to handle missing values only on candidate variables (outcomes were not imputed). Outcome variable was considered as a predictor only in the derivation dataset. We used predictive mean matching (PMM) method for continuous predictors and polytomous regression for categorical variables (two or more unordered levels). The results of 10 imputed datasets, each with 10 iterations, were combined following Rubin's rules 25 . Patients who were admitted before July 31 were included in the development cohort. First, we conducted predictor selection based on clinical reasoning and literature review before modeling. Second, generalized additive models (GAM) were used to examine the relationships between in-hospital mortality and continuous (through penalized thin plate splines) and categorical (as linear components) predictors. During this stage, variable selection was based on D1-(multivariate Wald test) and D2-statistic (pools test statistics from the repeated analyses). Third, for an easier application of the risk score model at bedside, continuous variables were categorized based on widely accepted cut points, current evidence and/or categories defined in stablished rapid scoring systems from pneumonia and sepsis. Lastly, we used least absolute shrinkage and selection operator (LASSO) logistic regression to derive the mortality score by scaling the (L1 penalized) shrunk coefficients. The penalty parameter λ in LASSO was chosen using 10-fold crossvalidation methods based on mean squared error criterion. Risk groups were proposed based on predicted probabilities: low risk ( < 6.0%), intermediate risk (6.0 -14.9%), high risk (15.0 -49.9%), and very high risk (≥ 50.0%). We performed an external (temporal) validation analysis using patients who were admitted from August 1 to September 30, 2020. The same investigators collected those data, and missing data were handle as described above. Independent external validation was also performed in a cohort of patients from Vall d'Hebron University Hospital (Vall d'Hebron COVID-19 Prospective Cohort Study), a 1100-bed public tertiary care hospital with the capacity for more than 60 ICU beds, in Barcelona, Spain 26 , part of the public hospital network of the Catalan Health System. Inclusion and exclusion criteria were the same as the beforementioned ones. All patients included were followed for at least 28 days. We evaluated overall performance using Brier score 27 . Calibration was assessed graphically by plotting the predicted mortality probabilities against the observed mortality, testing intercept equals 0 and slope equals 1. The area under the curve for receiver operating characteristic (AUROC) described model's discrimination, i.e, its ability to predict higher risks for individuals who died than for those who were discharged. Confidence intervals (95% CI) for AUROC were obtained through 2000 bootstrap samples. We also calculated positive and negative predictive values of the derived risk groups. The developed model was compared within the validation cohort with existing rapid scores systems for in-hospital mortality in COVID-19 patients. These scores were identified through a literature search of Medline, medRxiv and BioRxiv, with no language or date restrictions, using the search terms "COVID-19," "COVID", "SARS-CoV-2," "coronavirus" combined with "score" and "mortality". The last search was . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250306 doi: medRxiv preprint performed on November 19, 2020. Two authors independently performed article selection and data extraction. Additionally, we also included established scores for pneumonia and sepsis 28-32 . From the set of identified scores, we selected those which with predictors were available within the database and had accessible methods for calculation. Model comparisons were performed using AUROC and decision curve analysis, which describes clinical utility across a range of threshold risks, i.e, the relative value of benefits (if a true positive case is treated) and harms (if a false positive case is treated). Risk score calculator was developed in Javascipt, using the Svelte framework while the website was developed in R language (blogdown package). The study protocol conforms to the ethical guidelines of the Declaration of Helsinki. It was approved by the Brazilian National Commission for Research Ethics (CAAE 30350820.5.1001.0008) Individual informed consent was waived due to the severity of the situation and the use of deidentified data, based on medical chart review only. For the independent external validation cohort, it was approved by the and Vall d'Hebron University Hospital Research Ethics Committee (PR(AG)183/2020). The institutional review board granted an informed consent waiver if patients were unable to give oral consent. This was an urgent public health research study in response to a Public Health Emergency of International Concern. Patients or the public were not involved in the design, conduct, interpretation or presentation of results of this research. demographic, clinical characteristics and laboratory findings for the derivation and validation datasets. Thirty-six potential predictor variables were identified (Table S2 ). Number of comorbidities was created as a composite of ten individual comorbidities shown to have prognostic impact in COVID-9 (hypertension, diabetes mellitus, obesity, coronary artery disease, heart failure, atrial fibrillation or flutter, cirrhosis, cancer and previous stroke) 33,34 , as in other scores 35, 36 . Twelve variables were excluded due to the excessive number of missing values, two for high collinearity, and one was not recorded within database. Besides that, inotrope use was combined with blood pressure. Therefore, 20 variables were tested. Through generalized additive model (GAM), a combination of seven variables was selected as the best predictor of in hospital mortality (Table S3) . For an easier application to the risk score model at bedside, continuous selected predictors were categorized for LASSO logistic regression. All categories were defined a priori, as recommended, 20 based on widely accepted cut points, current evidence and/or categories defined in stablished rapid scoring systems from pneumonia and sepsis, as follows: advanced age (60-69.9, 70-79.9 and ≥ 80 years), Spo2/Fio2 (SF) ratio (≤ 150.0, 150.1 -235.0, 235.1 -315.0, > 315.0), platelet count (<100x10 9 /L, 100-150x10 9 /L, > 150x10 9 /L), C-reactive protein (≥100mg/L), blood urea nitrogen (BUN) (≥42mg/dL), heart rate (≤ 90, 91-130, ≥ 131 bpm). All variables were statistically significant predictors for in hospital mortality (Table S4 and Figure S1 ). Shrunk coefficients were scaled to provide a prognostic index and we denoted it as the ABC 2 -SPH risk score ( Table 2 ). The sum of the prediction scores ranges between 0 and 20, with a high score indicating higher risk of in-hospital mortality. Risk groups were proposed based on predicted probabilities (Table 3) : low risk (0-1 score, observed in hospital mortality 2.0%), intermediate risk (2-4 score, 11 .4%), high risk (5-8 score, 32.0%), and very high risk (≥ 9 score, 69.4%). Subject-specific risks can be assessed using the developed ABC 2 -SPH risk score Web-based calculator (https://abc2sph.com/), freely available to the public. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2021. ; As well as GAM and LASSO, ABC 2 -SPH risk score showed good overall performance (Brier score: 0.114) and good discrimination (AUROC equal 0.842; 95% CI 0.840-0.843) within the derivation cohort (Table 4) . A total of 1054 patients were included in the validation cohort. The median age was 62 (interquartile range 48-73) years, 582 (55.2%) were male and 745 (70.7%) had at least one comorbidity. The median follow-up time was 7 (4-13) days. Two hundred and eight patients (19.7%) died during hospitalization. The distribution of patients across range ABC 2 -SPH Score in derivation and validation cohorts are presented in Figure 3 . We observed good discrimination (AUROC equal 0.859; 95% CI 0.833 to 0.885; Figure 4 ), overall performance (Brier = 0.108) and calibration (slope = 1.138, intercept = 0.114, p-value = 0.184; Figure S2a ) of the ABC 2 -SPH risk score under the validation cohort ( Figure 4 ). The good performance is also demonstrated in sensitivity analyses using complete case data (Table S5) Figure 4 ), good overall performance (Brier = 0.093), but an underestimation of true mortality risk in patients with a predicted probability above 25% (intercept = 0.729, slope = 1.519, p-value = 0.001; Figure S2b ). The literature search identified 39 scores to predict mortality in COVID-19 patients ( Table 5 ). Most of them were still preprints (28%), in 36% the derivation cohort was from China, 21% from the United States and none from South America. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2021. ; Multivariate logistic regression and LASSO regression were used in 16 and 10 studies, respectively, artificial intelligence techniques in seven studies and Cox regression analysis in 3 studies. Two scores were developed by consensus. The population of the development cohort was composed by adults-only in 51.3% of the studies, the age range was not clear in 41.4% and elderly patients in one of them. Thirteen studies developed points-based scores, three were published as nomograms and all the other ones required formulas for calculation. From the 27 (69.2%) developed scores to predict in-hospital mortality, in three studies the full information required for proper calculation was not available, in five studies the assay used for D-dimer or troponin was not described to allow proper comparison, in two studies the variables were not clearly defined (such as "kidney failure", "elevated" CPR, and "cardiovascular and pulmonary comorbidity"), in two the variables were not applicable for other populations (such as province and coming from Wuhan), and in 12 one or more variables required were not in our study protocol. Based on complete case validation cohort, the ABC 2 -SPH score achieved better discrimination ( Table 6 , Figure 5a ) than other prediction scoring systems for COVID-19, pneumonia and sepsis (0.85; 95%CI: 0.82 -0.88). Xie's and Zhang's score 8, 37, 38 showed good discrimination, but the number of complete cases and deaths were relatively small. Considering clinical utility (Figure 5b ), ABC 2 -SPH showed a better performance compared to the two most discriminating scores for in-hospital mortality that were tested in more than 700 patients (A-DROP and CURB-65 29 ). COVID-AID-7 and COVID-AID-14 were not included, as they have assessed 7 and 14 day-mortality, respectively, and not in-hospital). ABC 2 -SPH score is simple, objective, easily available at hospital admission and easily calculated, employing seven well defined and routinely recordable variables: age, blood urea nitrogen, number of comorbidities, C-reactive protein, SpO2/FiO2 ratio, platelet count, heart rate. It has shown to be a reliable tool to estimate in-hospital . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2021. ; mortality in COVID-19 patients, although true mortality risk is somewhat underestimated in very high risk patients. Model performance compared surpassed other existing scores. The pandemic of COVID-19 disease has inflicted a heavy burden on the healthcare system of numerous countries. Little is known about how long the immune system will remain protective after vaccination or recovery from infection, and scientists have been predicting that SARS-CoV-2 "is here for the long haul" 39 . Therefore, it is of utmost importance to better identify those patients with higher risk of mortality, to inform early interventions and the need of more frequent repetitive assessments, to reduce the risk of death. The majority of developed scores are limited by methodological bias in development cohorts. Our prediction model was developed based on a large sample size of consecutive adult patients with confirmed COVID-19, from hospitals of different sizes, types and locations, to minimize the selection bias. Robust models require large sample sizes, which produce more reliable and accurate results 19 . It is estimated that 10-15 outcome events per predictor are required 40 . Among the models analyzed for comparison, only 30.8% used a sample with more than 1000 patients, 41.0% used a sample with less than 500 patients, and 41.0% were developed and validated in a sample with less than 100 events. All studies have missing data 19 , this reality may be due to lack of standardization of the necessary exams at hospital admission, and differences in resources available in hospitals for carrying out tests. The approach of excluding the missing data and performing the analysis with the complete cases can lead to biased results, since the complete cases may not adequately represent the entire original study sample, generating a selection bias 19 . To avoid this type of bias, in our model multiple imputation with chained equations (MICE) was used to handle missing values on potential predictors, where the foul was assumed at random. Most of the models we analyzed for comparison (69.2%) did not perform or did not describe whether imputation methods were used for the missing data, therefore, there is a high risk of bias related to the treatment of missing data. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2021. ; As the accuracy of a prediction model is always high whether the model is validated on the development cohort used to derive the model only, the assessment of accuracy in those studies may be overoptimistic. It is important that studies that develop prediction models use some validation method to quantify any optimism in the predictive performance of the model developed and adjust the model for overfitting 19 . In 43.6% of the analyzed studies, external validation of the developed model was not performed. External validation is highly recommended to assess the performance of a prediction model on other participant data that was not used for the development of the model 19 . Previous studies have observed the variables included in the ABC 2 -SPH score as risk factors for severe COVID-19, what shows that our results are in line with the available evidence. Age and number of comorbidities were reported as independent risk factors for developing severe COVID and mortality in several publications 10, 36, 41 . The strong age gradient per decade after 60 years-old is in line with other series 10, 14 . One of the main causes of death in COVID-19 patients is the unregulated immune response, with an uncontrolled production and secretion of cytokines. Aging is associated with a well-known decline in the adaptive and innate immunity, which plays a major role in the increased susceptibility of infections 42 . Age-related immune imbalance is also related to an increased severity in pro-inflammatory response and increased cytokine production, what is believed to increase patient vulnerability to the unregulated inflammatory response in COVID-19 43 . Other authors hypothesize that decreased lung elasticity, increased end-expiratory and abnormal alveolar integrity related to lung senescence, which may be associated to kidney senescence play a role in the predisposition for severe COVID-19 and mortality 10 . It is important to highlight the evidence of a decreased antibody production following immunization in the elderly, as well as shortened duration of protective immunity 43 . This might be the case for COVID-19 as well. Therefore, even being a priority group for the vaccine, this age group will probably remain a major risk factor for mortality. The number of comorbidities indicates the importance of pre-existing conditions to the severity of COVID-19. Even though comorbidities are age-dependent factors, the number of comorbidities remained as an independent risk factor in the final model. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2021. ; As we aimed to use variables easily available at ED admission of any institution, we opted to evaluate the ratio of peripheral oxygen saturation over the inspired fraction of oxygen (SpO 2 /FiO 2, SF ratio), instead of the ratio of arterial oxygen partial pressure over the fraction of inspired oxygen, like the COVID-AID score 44 . Arterial blood gas puncture and analysis is an invasive and complex procedure, which may be time consuming for the team. Additionally, a recent publication highlighted that despite widespread familiarity with use of PaO 2 /FiO 2 ratio using blood gas analysis, clinical recognition of acute respiratory distress syndrome remains poor 45 . The authors assessed 28,758 mechanical SF ratio and PaO 2 /FiO 2 ratio in mechanical ventilated patients, and observed that PaO2/FiO 2 ratios were substantially less available or even unavailable in a significant proportion of ventilated patients 45 . SF ratio was already validated as a substitute for the PaO 2 /FiO 2 ratio in assessing the oxygenation criterion of patients with acute lung injury and acute respiratory distress syndrome 46 . COVID-19 associated hyperinflammation and coagulopathy are correlated to with a wide deviation in various inflammatory markers and hemostasis parameters, including C-reactive protein, thrombocytopenia, D-dimer and prothrombin time, and thus these are potential prognostic markers of increased mortality in COVID-19 47,48 . Consistent with prior studies, we also observed utility of CRP thrombocytopenia. C-reactive protein in an acute phase reactor with established prognostic prediction role in intensive care septic and non-septic patients 49,50 , and it has been included in different scores an independent predictor for mortality. 51, 52 The prognostic value of thrombocytopenia in patients with COVID-19 has shown in a recent meta-analysis 53 , and it was also included in other scores 10, 51 . The exact explanation is still unknown, and it is probably multifactorial, related to direct infection of bone marrow cells by the virus, resulting in abnormal hematopoiesis; platelet destruction by the immune system; endothelial damage triggering platelet activation, aggregation and microthrombi in the lung; and abnormal platelet defragmentation in the lungs 53 . A recent meta-analysis of 16 studies, which included 2783 surviving and 697 non-surviving cases, has shown significantly higher levels of D-dimer on admission in patients who died compared to the ones who were discharged 47 . This exam was included as a predictor in different scores 13, 16, 52, 54, 55 . Although D-dimer was collected in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250306 doi: medRxiv preprint our study, D-dimer assays varied widely among different hospitals. Ideally, the value has to be determined with the same methodology, preferably from the same manufacturer, and this information was not available in any of the studies. Most studies have not reported how they dealt with cases who were transferred between hospitals. Although SOFA scores tend to be low at hospital admission, Zhou et al 57 observed that age, SOFA score and D-dimer at admission were independent risk factors for mortality. However, they opted to include those patients, even patients with late stage COVID-19, using admission data from the second hospital only. It is quite likely there was a higher chance those patients were already with critical disease 57 . As the score is intended to be used at hospital admission, we opted to exclude patients who were transferred between hospitals and admission data from the first hospital was not available. Blood urea nitrogen elevation was a strong predictor for mortality, what is in line with other scores 36,58,59 . Kidney disease has been widely described as a risk factor for in-hospital mortality. Although autopsy studies did not find conclusive evidence of SARS-CoV2 infection in the kidney, some authors hypothesize that the damage may be mediated by direct cytopathic effects of SARS-Cov2 on the kidney tissue, immunemediated damage due to virus-induced immune complexes, as well as the effects of the inflammatory response, hypoxia and shock 60-62 . A major strength of this rapid scoring system is its simplicity, the use of objective parameters, what helps to reduce inter-user variability, easily available at the emergency department presentation, even in under-resourced settings. A major strength of this study is that it followed strict methodological criteria, recommended by TRIPOD . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In a huge country such as Brazil, the development of a score that truly corresponds to the reality of our population's characteristic was only possible by the collaborative work among several hospitals from all the regions of the country. The COVID-19 cause and requirement for agile answers from the scientific community motivated the fast and precise teamwork and allowed the achievement of the creation of a tool to support the daily work in the frontline to combat the pandemic. We believe that the learning regarding the development of qualified and useful research engaging several centers could allow us to generate more accurate and faster results to subside health policies in the future. Patients who were transferred to other hospitals and thus were lost to follow-up do not characterize selection bias, as they similar characteristics of the development and validation cohorts, and a risk similar to those cohorts: of the 77 patients, 53 presented complete data and had their scores calculated -low risk 30.2%, intermediate 35.8%, high 22.6%, very high 11.3%. With regards to study limitations, it was a retrospective analysis subject to the drawbacks of patient records review. Obesity was not directly measured by body mass index, but rather clinical defined, gathered from medical records, which may have led to underreporting. Due to the pragmatic study design, laboratory tests were performed at the discretion of the treating physician, and we did not have a full dataset on all laboratory parameters of interest available. Some laboratory parameters, which proved . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2021. ; to be of prognostic relevance in other studies, were not available for at least 2/3 of patients in our sample. Therefore, we cannot rule out that variables with a higher proportion of missing data would have had a significant impact on mortality prediction. Additionally, we were unable to assess the predictive ability of some scores, as some required variables were not available. Another bias from the Spanish validation cohort is the fact that the majority of those patients came from the beginning of the pandemic, and management of the patients improved during subsequent waves. Data include 28-day mortality, which may differ from the Brazilian data, although the score was able to show very good discrimination. ABC 2 -SPH score may be very useful in a real-world setting, to provide healthcare practitioners the decision support that is needed to help them better identify and prioritize the care of patients who have the higher risk of death. Its development and validation followed strict methodological criteria, and the score fulfils the majority of the characteristics of an ideal score 63 . It can be used in all emergency departments, regardless of the level of resource settings. The results represent the experience of 36 hospitals in 17 cities in Brazil, and one hospital in Spain, and they are highly relevant to the current pandemic. It can be easily calculated at bedside or could be easily integrated to the electronic medical records for an automatic computation. It may help clinicians to identify high-risk patients from the triage phase, as well as to identify those most appropriate to be enrolled into therapeutic trials, may make possible to expand inclusion criteria through the early identification of patients who may benefit from therapy 64 . It might also be useful to help guiding recommendations for early palliative Different from what has been mistakenly suggested 36,67-69 , the results from this study do not suggest that patients from low-risk group may be discharged for home treatment. No score so far has specifically tested this hypothesis. A recent editorial has highlighted the importance of taking into account the "treatment paradox": patients identified to be at the low risk group were at low risk due to the interventions received in hospital 70 . It must not be interpreted as the risk to a patient if no actions are taken. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. ; Sperrin & McMillan counterfactual prediction modelling as a potential solution to minimize bias from treatment paradox 70 . More importantly, due to the treatment paradox, scoring systems developed and validated in in-hospital settings cannot be used in outpatient settings without further validation, as it has been mistakenly suggested 71 . We believe that ABC 2 -SPH score may hold potential generalizability for other countries. However, prediction models are population specific and may produce different results in different populations 72 . Considering that thresholds for admission may vary, hospitalized COVID-19 population may be different, the outcome events are different and patient management may be different, further validation (and recalibration) in different health care settings is recommended. In particular, we learned that our model might underestimate mortality in high-risk individuals. As we opted to develop the score focusing on information available at admission, as this would make it more useful for clinicians, other important factors during hospitalization that may impact prognosis were not included. Further analysis involving these factors are required. Future studies may also investigate risk factors for mortality among patients who develop COVID-19 symptoms during hospital admission due to other conditions. In conclusion, we developed and validated the ABC 2 -SPH rapid scoring system and a web-based risk calculator. This score, based on age, number of comorbidities, blood urea nitrogen, C-reactive protein, platelet count, peripheral oxygen saturation and oxygen support at admission is an inexpensive tool, showed to objectively and accurately predict in-hospital mortality in COVID-19 patients. It may be used at bedside for earlier identification of in-hospital mortality risk and, thus, inform clinical decisions . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. ; and the assignment to the appropriate level of care and treatment for COVID-19 patients. We would like to thank the hospitals which are part of this collaboration, for We also thank all the clinical staff at those hospitals, who cared for the patients, and all undergraduate students who helped with data collection. The sponsors had no role in study design; data collection, management, analysis, and interpretation; writing the manuscript; and decision to submit it for publication. MSM and MP had full access to all the data in the study and had responsibility for the decision to submit for publication. The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250306 doi: medRxiv preprint Data are available upon reasonable request. The lead authors (MSM and MCP) affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned (and, if relevant, registered) have been explained. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. ; Tuty . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. ; Nicholson . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. ; . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. ; . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. Several potentially relevant comorbidities, such as hypertension, previous myocardial infarction, and stroke, were not included in data collection. The authors considered that inclusion of these comorbidities might have impacted upon or improved the performance and generalizability of the 4C Mortality Score. Secondly, a proportion of recruited patients (3.3%) had incomplete episodes, so there is a possibility of selection bias, if patients with incomplete episodes, such as those with prolonged hospital admission, had a differential mortality risk to those with completed episodes. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. 56 Kazemi 75 Age, sex, comorbidity (cardiovascular and pulmonary), diffused distribution of CT abnormality, total CT-score and dyspnea at admission No Logistic Regression 0.73 (95% CI not reported) NA Small sample size and number of events. Too many variables tested for the low number of events. Comorbidities were not well defined, percentage of involvement included in CT score is subjective and peripheral involvement is not well defined. Complete case analysis. High risk of selection bias: All 3 hospitals were referral centers for COVID-19 patients, so it is possible that the overall CT-score of the patients in this study would not be representative of the general population Authors reported that some incident events in the participating centers may not have been diagnosed and/or not been reported. The data analysis and modeling focused on only two countries (Italy and Spain) of the four initially considered, since as previously mentioned heterogeneity among countries with regard to clinical features and death-risk assessment could limit the representative nature of the sampling. Small sample size of both development and validation samples. Too many predictors tested for a small number of events. Complete case analysis. External validation sample not described. The external sample consisted of patients from a regional non-university hospital, which could explain the differences on catchment area and patient recruitment. In the acute context of the first SARS-CoV-2 epidemic wave in France, we relied on a sample prospectively defined by consecutive eligible patients in the study center. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint NA Single-center study, with small sample size, including cases not confirmed by RT-PCR, and less than 100 events. Complete-case analysis and tests too many variables for the number of events. D-dimer assay not . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. Single-center study, with small sample size, including cases not confirmed by RT-PCR, and less than 100 events. Complete-case analysis and tests too many variables for the number of events. The use of data collected from a sentinel surveillance system model, what raises concern about data quality. The same score for inpatient and outpatients and sensitivity analysis was not performed to assess accuracy for patients who were hospitalized. Apparently, complete case analysis. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint High risk of selection bias: the cohort was conducted early in the pandemic, there was a high mortality rate (51.8% in development cohort and 47.6% in the validation cohort), and it may not accurately represent patients with mild or asymptomatic COVID-19 (as they were not being tested). Small sample size for development and validation, less than 100 events both. Complete case analysis. Glasgow coma scale, oxygen support level, BUN, age, lymphocyte percentage, troponin Points-based score Not reported, as AUC was used to define the variables for the score. At admission 0.81; maximum through admission 0.91; mean through admission0. 9 2 The authors reported that documentation of all kinds was inconsistent during the first wave of covid-19, and the environments at different hospitals varied substantially. While it is unlikely that a laboratory result or medication administration was missed, inconsistencies in flowsheet documentation during this period could mean that the timings of different modes of oxygen administration were not always accurately capture. The statistical test used to produce the score is not adequate according to the TRIPOD and may lead to overoptimism. Authors reported that clinical datasets were collected when healthcare services were under severe strain. Data extraction sought to ensure consistency and accuracy, but there is missing data in both datasets, and the analysis was complete case based. Sample sizes for development and validation were small, with <100 events. Clinical assessments at admission such as SpO2 were not available in either dataset. The external validation dataset has very different case-mix, and only had follow-up to a fixed date (6-39 days). Although the Wuhan cohort includes many people with less severe disease, in the validation . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. As it includes inpatients and outpatients, important laboratory parameters were not tested. The authors reported that the clinical features available were limited to those routinely collected during hospital encounters, and they pointed out that development of even better prediction models should be possible using a richer set of features. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. Single-center study, with small sample for development and validation, less than 100 events in the validation cohort. Apparently, complete-case analysis. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. The auhtors reported they were unable to develop a model on COVID-19 patient data due the scarcity of databases that contains this information in sufficient numbers. Based on seconday data, with possibility of misclassifications of predictors (diseases is incorrectly recorded in a patient's history, incorrect recording of influenza or COVID-19, and authors were unable to include some suspected diseases predictors such as BMI/obesity in the analysis due to the inconsistency with which these mesures are collected and reporte across the databases included in the study. Patients may day after 30 days, and this will be recorded as a non-event. Apparently, complete case analysis. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. ; . It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. ; For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors 14 Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful 15, Figure 1 13b Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome 15, Table 1 13c For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome) Table 1 Model development 14a Specify the number of participants and outcome events in each analysis Table 1 14b If done, report the unadjusted association between each candidate predictor and outcome NA Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point) Table S4 15b Explain how to use the prediction model Page 16, Table 2 Model performance 16 Report performance measures (with CIs) for the prediction model Table 4 , Table S5 Model updating 17 If done, report the results from any model updating (i.e., model specification, model performance) Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2021. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. Was the time interval between predictor assessment and outcome determination appropriate? Yes (time interval between predictor assessment and outcome determination was appropriate) Yes (time interval between predictor assessment and outcome determination was appropriate) Risk of bias introduced by predictors or their assessment: low risk of bias. Analysis Were there a reasonable number of participants with the outcome? Yes (high number of events per variable). Yes (number of participants with the outcome is ≥ 100) Were continuous and categorical predictors handled appropriately? Yes (continuous predictors are examined for nonlinearity using thinplate splines and then categorical predictor groups were defined using widely accepted cut points, current evidence and/or categories defined in stablished rapid scoring systems). Yes (predictors were used as in the development model). Were all enrolled participants included in the analysis? Yes (all participants enrolled in the study were included in the data analysis). Yes (all participants enrolled in the study are included in the data analysis). Were participants with missing data handled appropriately? Yes (missing values were handled using multiple imputation methods) Yes (missing values are handled using multiple imputation methods) Was selection of predictors based on univariable analysis avoided? Yes (the predictors were not selected on the basis of univariable analysis prior to multivariable modeling) NA 4.6 Were complexities in the data (e.g., censoring, competing risks, sampling of control participants) accounted for appropriately? Yes (a full cohort approach was used -median follow-up time was 7 days) Yes (a full cohort approach was used -median follow-up time was 7 days) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. coefficients in the final model correspond to reported results from multivariable analysis) Risk of bias introduced by the analysis: low risk of bias. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2021. ; https://doi.org/10.1101/2021.02.01.21250306 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 3, 2021. ; COVID-19) Weekly Epidemiological Update and Weekly Operational Update Fair Allocation of Scarce Medical Resources in the Time of Covid-19 Coronavirus disease (COVID-19) The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem A Troubling New Pattern Among the Coronavirus Variants Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings Development and validation of a risk factorbased system to predict short-term survival in adult hospitalized patients with COVID-19: a multicenter, retrospective, cohort study Prediction models for COVID-19 clinical decision making. The Lancet Digital Health Clinical risk score to predict inhospital mortality in COVID-19 patients: a retrospective cohort study Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: An observational cohort study Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal Thrombo-inflammatory features predicting mortality in patients with COVID-19: The FAD-85 score Development of a multivariate 69 A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: an observational cohort study Prediction models for covid-19 outcomes A Novel Scoring System for Prediction of Disease Severity in COVID-19 Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration Patient Trajectories Among Persons Hospitalized for COVID-19: A Cohort Study COVID 19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission Prognostic factors of chest CT findings for ICU admission and mortality in patients with COVID-19 pneumonia Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry Predicting mortality due to SARS-CoV-2: A mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico Development and calibration of a simple is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 3, 2021. Included? No. Ccongenital heart disease not available. Fumagalli 10 No. Depression and dementia were not categorical variables in the present study. No. Dementia was collected as a free-text field, and could not be cathegorized up to the data this study was submited. No. Composite outcome. No. Mean corpuscular volume not available. Garibaldi 73 No. Nursing home resident and BMI not available. Sourij 74 No. Arterial onclusive disease not available. No. SpO2 and respiratory rate after 15-minute trial with oygen not available. Kazemi 75 No. Comorbidities were not well defined, percentage of involvement included in CT score is subjective and peripheral involvement is not well defined.Núñez-Gil 76 No. Variables not cleary defined (renal failure and elevated C-reactive protein). Allenbach 14 No. Composite outcome. No. CK-MB not available. No. IL-6 not available, intercept not provided for calculation.Hajifathalian 44 Yes Wang J 13 No. D-dimer assay not described by the authors. No. D-dimer assay not described by the authors. No. The authors did not provide all ifnormation necessary to calculate the score. No. Ethnicity not available. No. As the score was developed considering outpatients and inpatients, the comparison would not be appropriate. No. D-dimer assay not described by the authors. No. Not all predictors are availabe, such as RDW.Xie 37 Yes Yoo 79 No. Troponin assay not described by the authors. Zhang 38 No. Very limited study, most included variables had OR with 95% CI including 1.0. No. Ethnicity not available. No. D-dimer assay not described by the authors. No. Information to allow calculation was not provided. No. Variables such as province not applicable for other populations. No. Authors did not show how to calculate the score. No. Authors did not show how to calculate the score. No. Some variables applicable only to the Chinese population, in the beggiing og the pandemic. No. D-dimer assay not described by the authors.